NAFLD-Associated HCC: Progress and Opportunities
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Due to an increase in the obesity-associated metabolic syndrome of epidemic proportions, nonalcoholic fatty liver disease (NAFLD) is becoming a leading cause of hepatocellular carcinoma (HCC) in western countries. This presents added challenges, as NAFLD-associated HCC tends to present at an advanced stage in older patients with co-morbidities. Their prognosis is generally poor with the benefits of standard therapies less certain. The pathogenesis of NAFLD-associated HCC is multifactorial and not well understood, although the risk of HCC developing undoubtedly increases as NAFLD progresses to steatohepatitis and cirrhosis. Recent advances in our understanding of the drivers of NAFLD and HCC will hopefully lead to the development of clinically relevant biomarkers, tools and strategies to aid the identification of high-risk patients, inform preventive measures, and introduction of better tolerated targeted therapies. Lifestyle modification and chemoprevention with drugs such as anti-platelets, statins and anti-diabetics are being evaluated for HCC prevention. The landmark IMBrave150 study introducing the combination of atezolizumab and bevacizumab has recently transformed the landscape of systemic therapies in HCC, with follow-up analyses and real-world data for patients with NAFLD-associated HCC eagerly anticipated. While responses may vary in ways not yet appreciated, the rate of discovery and progress suggests imminent change and opportunities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“11,13 16 The huge patient population, combined with the lack of inexpensive, non-invasive and reliable biomarkers, makes identifying NAFLD patients with progressive disease and those at most risk of developing HCC extremely difficult.”
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479 · cited 1×
“for advanced HCC, based on data from non-randomized clinical trials.(135,136) As a first line therapy, the randomized”
MethodGender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
Naugler, W. E., Sakurai, T., Kim, S., Maeda, S., Kim, K., Elsharkawy, A. M., & Karin, M. (2007) · Science · doi:10.1126/science.1140485 · Cited by 1,955
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 1×
“93,94 Immune escape from anti-tumour responses is also vital, with populations of T regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs) exerting immunosuppressive effects on cytotoxic CD8 + T cells and natural killer (NK) cells.”
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392 · cited 4×
“29 An association between microbiome dysbiosis and NAFLD-HCC has also recently been reported.”
InfluentialSelf-citationZhang, X., Coker, O. O., Chu, E. S., Fu, K., Lau, H. C. H., Wang, Y.-X., Chan, A. W. H., Wei, H., Yang, X., Sung, J. J. Y., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-319664 · Cited by 841 · cited 2×
“mice into germ-free mice fed with normal chow who then developed NAFLD and increased hepatocyte proliferation.(115)”
BackgroundYounossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648 · cited 1×
“18 24 Published series indicate that patients with NAFLD-HCC generally have a worse prognosis compared to HCC of other etiologies.”
Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623 · cited 1×
“…TM6SF2 rs58542926 is again associated with NAFLD progression to fibrosis but has conflicting reports of its independent association with HCC. 42 Although a recent meta-analysis of 5 studies including a total of 6873 patients has confirmed an independent association, 46 the requirement for…”
Self-citationPiscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604 · cited 3×
“patients may live for longer receiving best supportive care.(4,19,21,22,26)”
BackgroundInfluentialHepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.011 · Cited by 603 · cited 2×
“4,19,21,22,26 The Changing Landscape and Immuno-Oncology Therapies Sorafenib has been the first-line systemic therapy for HCC for the last decade, with Lenvatinib coming on to the scene as an equally effective alternative – with a different side effect profile, over the last 2 years.”
Buch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565 · cited 1×
“39,40,43,47 TM6SF2 rs58542926 is again associated with NAFLD progression to fibrosis but has conflicting reports of its independent association with HCC. 42 Although a recent meta-analysis of 5 studies including a total of 6873 patients has confirmed an independent association, 46 the requirement…”
Liu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.030 · Cited by 549 · cited 1×
“PNPLA3 rs738409 confers an increased risk of steatohepatitis and fibrosis in both European and Japanese populations and is an independent risk factor for the development of HCC.(41,44,45) MBOAT7 rs641738 confers risk of fibrotic progression in a number of etiologies of chronic liver disease, including NAFLD and has be…”
BackgroundSelf-citationMalehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398 · cited 2×
“95 While encouraging, larger studies are needed to confirm the potential of anti-platelet therapy in preventing NAFLD progression and HCC.”
Relationship Between Methylome and Transcriptome in Patients With Nonalcoholic Fatty Liver Disease
Murphy, S. K., Yang, H., Moylan, C. A., Pang, H., Dellinger, A., Abdelmalek, M. F., Garrett, M. E., Ashley–Koch, A., Suzuki, A., Tillmann, H. L., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.047 · Cited by 391 · cited 1×
“74,75 Importantly the methylation of circulating cell-free DNA (cfDNA) can be analysed.”
Bianco, C., Jamialahmadi, O., Pelusi, S., Baselli, G., Dongiovanni, P., Zanoni, I., Santoro, L., Maier, S., Liguori, A., Meroni, M., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.024 · Cited by 385 · cited 1×
“Going forward, both sensitivity and specificity may be improved using combinations of SNPs and Bianco et al have recently reported the development of a polygenic risk score, combining SNP data from PNPLA3, TM6SF2, and MBOAT7, as well from glucokinase regulator (GCKR) predicting an elevated risk, with that from another…”
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
Mouzaki, M., Wang, A. Y., Bandsma, R., Comelli, E. M., Arendt, B. M., Zhang, L., Fung, S., Fischer, S. E., McGilvray, I. G., & Allard, J. P. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151829 · Cited by 385
Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
Grohmann, M., Wiede, F., Dodd, G. T., Gurzov, E. N., Ooi, G. J., Butt, T., Rasmiena, A. A., Kaur, S., Gulati, T., Goh, P. K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.053 · Cited by 373 · cited 2×
“90 The identification of a pathway central to the development of HCC but not the fibrotic healing response makes it attractive to explore as a therapeutic target.”
Fujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0016-1 · Cited by 355 · cited 1×
“72 A recent study using this model revealed that increasing hypomethylation and overexpression of the tubulin beta 2B class IIB (Tubb2b) gene occurred during the development and progression of HCC. 73 Tubb2b overexpression was also found in the human HepG2 cell line suggesting this could be a…”
Mediterranean diet and nonalcoholic fatty liver disease
Anania, C., Perla, F. M., Olivero, F., Pacifico, L., & Chiesa, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i19.2083 · Cited by 353
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?
Nair, S., Mason, A., Eason, J., Loss, G., & Perrillo, R. P. (2002) · Hepatology · doi:10.1053/jhep.2002.33713 · Cited by 348
Stine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14937 · Cited by 336
Daniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., Karsdal, M. A., Grove, J. I., Neil Guha, I., Kawaguchi, T., et al. (2019) · Hepatology · doi:10.1002/hep.30163 · Cited by 273 · cited 3×
“100 Both scores were superior to current ‘simple scores’, such as FIB-4.”
BackgroundResultHardy, T., Zeybel, M., Day, C. P., Dipper, C., Masson, S., McPherson, S., Henderson, E., Tiniakos, D., White, S., French, J., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311526 · Cited by 216 · cited 1×
“76 Although this requires further validation this identifies circulating DNA methylation as a potential biomarker to identify patients with advanced NAFLD.”
Self-citationYang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R. (2020) · Hepatology · doi:10.1002/hep.30858 · Cited by 209
Simon, T. G., Henson, J., Osganian, S., Masia, R., Chan, A. T., Chung, R. T., & Corey, K. E. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.061 · Cited by 180 · cited 1×
“54, respectively) in patients taking aspirin compared to those not taking aspirin.(126) A large propensity score-matched cohort study of 50,275 patients with chronic HBV or HCV infection demonstrated a significantly lower incidence of HCC and liver-related mortality in patients taking aspirin compared to patients not…”
Zeybel, M., Hardy, T., Robinson, S. M., Fox, C., Anstee, Q. M., Ness, T., Masson, S., Mathers, J. C., French, J., White, S., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0056-6 · Cited by 180
Self-citationYoshida, S., Ikenaga, N., Liu, S. B., Peng, Z.-W., Chung, J., Sverdlov, D. Y., Miyamoto, M., Kim, Y. O., Ogawa, S., Arch, R. H., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.038 · Cited by 164
Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease
Boyle, M., Tiniakos, D., Schattenberg, J. M., Ratziu, V., Bugianessi, E., Petta, S., Oliveira, C. P., Govaere, O., Younes, R., McPherson, S., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.004 · Cited by 140
Self-citationLonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129 · cited 2×
“32,33 Gender-specific biological factors such as body fat composition, lipid metabolism and sex hormones likely contribute to this dimorphism in NAFLD.”
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017) · Medicine · doi:10.1097/md.0000000000006888 · Cited by 89 · cited 3×
“Chemoprevention Anti-Diabetic Drugs The chemopreventive properties of metformin have been demonstrated in a number of large studies.(116,117) Metformin may well have chemoprotective properties beyond its effect on diabetic control, as protection against HCC development is not conferred by other hypoglycemic drugs such…”
BackgroundMethodInfluentialModerate Exercise Inhibits Age-Related Inflammation, Liver Steatosis, Senescence, and Tumorigenesis
Bianchi, A., Marchetti, L., Hall, Z., Lemos, H., Vacca, M., Paish, H., Green, K., Elliott, B., Tiniakos, D., Passos, J. F., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001022 · Cited by 45 · cited 3×
“112 The exercise intervention reversed steatosis within the liver and reduced inflammation, oxidative damage and cellular senescence.”
Influential
Cited by
Song, Q., Zhang, X., Liu, W., Wei, H., Liang, W., Zhou, Y., Ding, Y., Ji, F., Ho-Kwan Cheung, A., Wong, N., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.005 · Cited by 293
Rusu, I., Pirlog, R., Chiroi, P., Nutu, A., Puia, V. R., Fetti, A. C., Rusu, D. R., Berindan-Neagoe, I., & Al Hajjar, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012370 · Cited by 27
Li, H., Liu, N.-N., Li, J.-R., Wang, M.-X., Tan, J.-L., Dong, B., Lan, P., Zhao, L.-M., Peng, Z.-G., & Jiang, J.-D. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113083 · Cited by 20
Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
Kahl, S., Pützer, J., & Roden, M. (2022) · Seminars in Liver Disease · doi:10.1055/s-0041-1732354 · Cited by 5
Metadata
- Authors
- Geh, D., Anstee, Q. M., & Reeves, H. L.
- Venue
- Journal of Hepatocellular Carcinoma
- Publisher
- Informa UK Limited
- Published
- 2021-04
- Volume
- Volume 8
- Pages
- 223-239
- ISSN
- 2253-5969 (ISSN-L)
- OpenAlex
- W3140237330
- Cited by
- 61
- References
- 35
- FWCI
- 5.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.